CatSci Ltd’s Post

🚨 **Avid Bioservices to Go Private in $1.1B Acquisition Deal** 🚨 Avid Bioservices, a leading biologics-focused contract development and manufacturing organization (CDMO), has entered into an agreement to be acquired by GHO Capital Partners and Ampersand Capital Partners in an all-cash transaction valued at approximately $1.1 billion. Under the deal, Avid’s Nasdaq-listed shares will be acquired for $12.50 per share, a 13.8% premium over the company’s closing price on November 6, 2024. Once the deal is finalized in Q1 2025, Avid will become a privately held entity, continuing to operate under its established brand and leadership. As a trusted provider of process development and CGMP manufacturing services for biotech and biopharma, Avid has seen significant growth, including a 6% increase in revenue in Q1 FY2025. Its strong order backlog, coupled with strategic investments in capacity and team development, position the company for continued success. **Nick Green**, President and CEO of Avid, shared, "Partnering with GHO and Ampersand will allow us to build on our strong foundation and further accelerate growth with the support of their capital and expertise." This acquisition reflects the growing demand for high-quality, efficient manufacturing of biologic therapies and further strengthens Avid’s position in the rapidly expanding biotech market. #Biotech #CDMO #AvidBioservices #Acquisition #Biopharma #HealthcareInnovation #Manufacturing #GHO #AmpersandCapital #PrivateEquity #LifeSciences #BusinessGrowth

#News: #Biopharma leaders will descend on San Francisco next week hopeful that the industry’s biggest dealmaking event will finally yield some much sought-after M&A. The industry needs it after a slow fourth quarter, which had the lowest number of deals and total quarterly value since the first quarter of 2022, according to a J.P. Morgan analysis published this week. There were only 18 M&A transactions in the final three-month stretch of 2024, compared to 31 in the same period in 2023. The total deal value was about one-tenth of 2023’s exuberant fourth quarter. “Somehow the bubbles in New Years’ champagne weren’t quite as robust as they might have been a year ago,” #Stifel’s Tim Opler wrote Tuesday. The biggest deal of 2024 was Vertex Pharmaceuticals’s $4.9 billion acquisition of Alpine Immune Sciences, Inc. in April. In a securities filing, Alpine said it held talks during the JP Morgan Healthcare Conference with four unnamed companies about its R&D plans before entering a confidentiality agreement with Vertex in mid-February. And as the meeting’s profile has risen, many investors and startup executives now expect a drumbeat of deals to kick the first quarter into gear, particularly this year since large drugmakers spent last year inking deals that hovered around $1 billion in value. “Note that some see this as [a] source of near-term downside risk if we don’t have a busy start to the year/JPM given expectations relatively high for a quick start,” Raymond James’ bankers wrote Sunday in a note. There were no megadeals or even medium-sized M&A in 2024, even though big pharma companies had about $1 trillion in cash and debt capacity for deals, according to a Jefferies report in August. Those companies with firepower appeared to play it safe, betting on early-stage private biotechs that likely would’ve been on the Nasdaq if the public markets weren’t so uncertain. Johnson and Johnson, Merck and Novo Nordisk have the most firepower, Jefferies analysts noted. It was the first year in more than two decades without a $5 billion or larger biopharma deal, according to William Blair. It was also the first year without a $10 billion deal since 2012, they wrote. The firm’s bankers predict 2025 will have “meaningful public company M&A” and about 30 IPOs. Read more from Endpoints News 👇🏼

Finally - a breakthrough in Hong Kong Exchanges and Clearing Limited (HKEX) with the first merger involving a Chapter 18A company Genor! A reverse merger at that with Eddingpharm. This is good for the Chinese #biopharma industry, as the perception has been that the stringent rules on the exchange reduced companies' flexibilities as the growth slowed. This first example illustrates that it is possible to unstuck oneself. Will take privates be next? https://lnkd.in/ghTz7tmn

Avid Bioservices Acquired for $1.1 Billion Avid Bioservices, a major player in biologics contract development and manufacturing, is set to be acquired by GHO Capital Partners and Ampersand Capital Partners for an impressive $1.1 billion. This acquisition marks a significant premium over Avid's recent share prices, reflecting strong confidence in Avid's robust growth trajectory. Avid Bioservices has been a cornerstone in the biotech and pharma industries, offering comprehensive development and manufacturing services. With this new backing, they can leverage GHO and Ampersand's vast resources and networks to further their mission. This move not only solidifies Avid's market position but also promises increased innovation and expanded service capabilities across Europe and the US. #LifeSciences #Biotech #HealthcareInvestments

Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) is seeking to relist its stocks on the #Nasdaq with a re-domiciliation to the United States under a scheme of arrangement that would see Delaware-based Anteris Technologies Global Corp become the parent company of the Anteris Group. The new holding company would then seek a listing on the Nasdaq – alongside a secondary listing of its CDIs on the ASX – and undertake an initial public offering (IPO) targeted at, but not restricted to, US investors. AVR plans to complete the relisting and the IPO by the end of 2024, targeting between US$75 million and US$100 million. More at #Proactive #ProactiveInvestors #NasdaqListing #IPO #Biotech #Biopharmaceutcials #MedicalDevices http://ow.ly/PxuI105FeNJ

Avid Bioservices Acquired for $1.1 Billion Avid Bioservices, a major player in biologics contract development and manufacturing, is set to be acquired by GHO Capital Partners and Ampersand Capital Partners for an impressive $1.1 billion. This acquisition marks a significant premium over Avid's recent share prices, reflecting strong confidence in Avid's robust growth trajectory. Avid Bioservices has been a cornerstone in the biotech and pharma industries, offering comprehensive development and manufacturing services. With this new backing, they can leverage GHO and Ampersand's vast resources and networks to further their mission. This move not only solidifies Avid's market position but also promises increased innovation and expanded service capabilities across Europe and the US. #LifeSciences #Biotech #HealthcareInvestments

Is this just the beginning for a new generation of biotech consolidators? In Q2, Genmab and Ono Pharmaceutical made their first acquisitions. Vertex inked its largest M&A deal since its founding. Incyte went back to the acquisition well after a brief period on the sidelines. Biogen quickly returned to shopping mode after having just digested its first acquisition in four years. Asahi Kasei forged a biotech consummation for the first time since 2019. “These emerging consolidators are sitting on meaningful cash reserves (average pro forma adjusted cash of $3.8 billion), thus paving the way for further M&A and/or stock buybacks as these companies face shareholder pressure to deploy this capital (e.g. Incyte’s $2.0 billion buyback in May 2024),” William Blair healthcare bankers wrote in their quarterly industry update. #biotech #pharma #mergersandacquisitions #consolidation #manda

⭐ Inflexion news - December Highlights ⭐ Here are just a few key milestones from the past month: 👏 We announced two new investments. 🎧 We released the latest Inflexion Point podcast with an interview featuring Medik8 Founder, Elliot Isaacs. (https://lnkd.in/eHAZzEC9) 🚀 Inflexion portfolio companies TC Group, Easyfairs and Ocorian celebrated acquisitions, while Sparta Global, ANS Group and K2 Partnering Solutions celebrated awards. 🔎 We took a deep dive into using data and #AI to accelerate sales growth, discussed the increasing complexities of clinical trials for #pharmaceutical companies, as well as the successful carve-out of GRC. You can see the full highlights on the Inflexion website: https://lnkd.in/eZVy6wkH Thank you to everyone for your support throughout 2024. We look forward to an exciting 2025 and wish you a wonderful festive season from all of us at Inflexion! 🎄 #BackingAmbition #AcceleratingGrowth

Exciting News from Suven Pharmaceuticals!  Suven Pharmaceuticals Ltd, owned by Advent, is exploring acquisitions in the technology space to boost our Contract Development and Manufacturing Organization (CDMO) platform. We're currently evaluating companies in oligo and peptide technology sectors, both domestically and internationally. This strategic move follows our recent agreement of 51% stake on fully diluted basis in Sapala Organics, enhancing our technology platforms like antibody-drug conjugates (ADCs) and Oligos. With a robust free cash flow and a strong cash bank balance, we are well-prepared to fund these acquisitions and continue our growth. Read the full VCCircle story here: https://lnkd.in/gmhfipmQ #suvenpharma #vccircle #technologyinvestment #acquisition VCCircle SREEJA BISWAS

Novo Holdings has completed its $16.5 billion acquisition of Catalent! This global CDMO has been supporting drug development and manufacturing and operating across 40+ sites worldwide, including facilities in Italy, the USA, and Belgium. Interestingly, Catalent has supported over 50% of FDA drug approvals over the past decade. Each year, it helps launch over 150 new treatments and delivers billions of doses to patients and playing a key role in advancing healthcare. This acquisition will be enhancing the drug development supply chain and manufacturing, ensuring critical therapies continue to reach patients globally. #Healthcare #DrugDevelopment #Biopharma https://lnkd.in/dbTKJGub